Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 16 Nov 2026
Standard addition

Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results.

Cemiplimab plus chemotherapy continues showing lasting survival benefits for advanced lung cancer patients five years after initial treatment.

This PubMed record examines Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results. It reports CONCLUSIONS: First-line cemiplimab plus chemotherapy continued to show durable clinical benefit versus placebo plus chemotherapy after 5 years of follow-up in PD-L1-positive advanced NSCLC.

What the study was

Study design
Phase 3 randomized controlled trial
Population
Human participants
Category
Treatment Innovation
Maturity
Validated
Journal
ESMO open

Why it surfaced

Phase 3 randomized controlled trial; conservative rapid-triage score based on PubMed title, publication type, and abstract.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.